October 26, 2018 - 9:00am

Health and Human Services Commission, John H. Winters Human Services Complex, Public Hearing Room
701 West 51st St.
Austin Texas, 78751

Agenda

Webcasting Available

1. Call to order
2. Approval of minutes from July 27, 2018 (vote required)
3. New member introductions and terms
4. Ethics policy refresher
5. Vice-chair election (vote required)
6. New business
    

   Public comment on drug classes and therapeutic and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL):

   1. Androgenic agents
   2. Antibiotics, GI
   3. Antibiotics, topical
   4. Antibiotics, vaginal
   5. Antiemetics/Antivertigo agents
   6. Antifungals, oral
   7. Antifungals, topical
   8. Antihistamines, first generation
   9. Antiparasitics, topical
   10. Antipsychotics
   11. Antivirals, oral
   12. Antivirals, topical
   13. Bone resorption suppression and related agents
   14. Colony stimulating factors
   15. Cytokine and CAM antagonists
   16. Epinephrine, self-injected
   17. GI motility, chronic
   18. Growth hormone
   19. Hepatitis C agents
   20. Hypoglycemics, incretin mimetics/enhancers
   21. Hypoglycemics, insulin and related agents
   22. Hypoglycemics, meglitinides
   23. Hypoglycemics, metformins
   24. Hypoglycemics, SGLT2
   25. Hypoglycemics, TZD
   26. Immunomodulators, atopic dermatitis
       aa. Macrolides/Ketolides
       bb. Ophthalmics, glaucoma agents
       cc. Opiate dependence treatments
       dd. Pediatric vitamin preparations
       ee. Penicillins
       ff. Tetracyclines
    

   Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:

   1. Aimovig / Antimigraine agents, other
   2. Mircera / Erythropoiesis stimulating proteins
   3. Osmolex ER / Antiparkinson’s agents
   4. Retacrit / Erythropoiesis stimulating proteins
   5. Roxybond / Analgesics, Narcotics short


7. Executive work session
    

   Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.

8. Announcements of drugs recommended for the Medicaid PDL (vote required)
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC
   1. Report on recent retrospective DUR interventions:
      1. Benzodiazepine anxiolytics and controlled sedative hypnotics
      2. Diabetes disease management
      3. Rheumatoid arthritis management
   2. Report on recent retrospective DUR intervention outcomes:
      1. Opioids during pregnancy
      2. Polypharmacy
      3. Stroke prevention
   3. Retrospective DUR proposals (vote required)
      1. Management of psychotropic drug in adults
      2. Medication adherence
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required)
    1. Calcitonin gene-related peptide receptor (CGRP) Antagonist - new criteria
    2. Cytokine and CAM antagonists - addition of Olumiant criteria
11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. 5-HT3 receptor antagonists
    2. Attention deficit disorder medications
    3. GLP-1 receptor agonists
    4. Oral antidiabetic agents
    5. Pramlintide
    6. Substance P / Neurokinin 1 receptor antagonists
12. Adjourn
13. Next meeting date: January 25, 2019

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-707-6112 or Maribel.Castoreno@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-meetings.

This meeting is open to the public. No reservations are required, and there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Castoreno at 512-707-6112 at least 72 hours before the meeting so appropriate arrangements can be made.